Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: Recommendations from the prostate- specific antigen working group

Journal of Clinical Oncology

Volumn 17, Issue 11, 1999, Pages 3461-3467

  Bubley, Glenn J ^a   Carducci, Michael ^a   Dahut, William ^a   Dawson, Nancy ^a   Daliani, Danai ^a   Eisenberger, Mario ^a   Figg, William D ^a   Freidlin, Boris ^a   Halabi, Susan ^a   Hudes, Gary ^a   Hussain, Maha ^a   Kaplan, Richard ^a   Myers, Charles ^a   Oh, William ^a   Petrylak, Daniel P ^a   Reed, Eddie ^a   Roth, Bruce ^a   Sartor, Oliver ^a   Scher, Howard ^a   Simons, Jonathan ^a   Sinibaldi, Vickie ^a   Small, Eric J ^a   Smith, Matthew R ^a   Trump, Donald L ^a   Vollmer, Robin ^a   Wilding, George ^a   more..

^a VANDERBILT UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN DETECTION; ARTICLE; BONE METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER RESEARCH; CLINICAL PROTOCOL; DRUG RESEARCH; HUMAN; PATIENT SELECTION; PRIORITY JOURNAL; PROSTATE CANCER; TREATMENT OUTCOME;

EID: 0032747375     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1999.17.11.3461     Document Type: Article

References (25)

1. Landis SH, Murray T, Bolden S, Wingo PA: Cancer statistics, 1998. Cancer J Clin 48:6, 1998
2. Huggins C, Stevens RE, Hodges CV: Studies on prostate cancer: II. The effect of castration on advanced carcinoma of the prostate gland. Arch Surg 43:209, 1941
3. Oh WK, Kantoff PW: Management of hormone refractory prostate cancer: Current standards and future prospects. J Urol 160:1220-1229, 1998
4. Figg WD, Ammermann K, Patronas N, et al: Lack of correlation between prostate-specific antigen and the presence of measurable soft tissue metastases in hormone-refractory prostate cancer. Cancer Invest 14:5137, 1996
5. Lilja H: A kallikrein-like serine prostease in prostatic fluid cleaves the predominant seminal vesicle protein. J Clin Invest 76:1899-1903, 1985
6. Pontes JE, Chu TM, Slack N, et al: Serum prostatic antigen measurement in localized prostatic cancer: Correlation with clinical course. J Urol 1216-1218, 1982
7. Schellhammer PF, Wright GL: Biomolecular and clinical characteristics of PSA and other candidate prostate tumor markers. Urol Clin North Am 20:597-606, 1993
8. Wang MC, Papsidero LD, Kuriyama M, et al: Prostate antigen: A new potential marker for prostate cancer. Prostate 2:89-96, 1981
9. Carter HB, Partin AW, Epstein JI, et al: The relationship of prostate specific antigen levels and residual tumor volume in stage A prostate cancer. J Urol 144:1167-1171, 1990
10. Scher HI, Mazumdar M, Kelly WK: Clinical trials in relapsed prostate cancer: Defining the target. J Natl Cancer Inst 88:1623-1634, 1996
11. Sridhara R, Eisenberger MA, Sinibaldi VJ, et al: Evaluation of prostate-specific antigen as a surrogate marker for response of hormone-refractory prostate cancer to suramin therapy. J Clin Oncol 13:2944-2953, 1995
12. Ferro MA, Gillatt D, Symes MO, et al: High dose intravenous estrogen therapy in advanced prostatic carcinoma: Use of serum prostate-specific antigen to monitor response. Urol 34:134-138, 1989
13. Seidman AD, Scher HI, Petrylak D, et al: Estramustine and vinblastine: Use of prostate-specific antigen as a clinical end point for hormone refractory prostatic cancer. J Urol 147:931-934, 1992
14. Smith DC, Dunn RL, Stawderman MS, et al: Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer. J Clin Oncol 16:1835-1843, 1998
15. Vollmer RT, Dawson NA, Vogelzang NJ: The dynamics of prostate specific antigen in hormone refractory prostate carcinoma: An analysis of Cancer and Leukemia Group B study 9181 of megestrol acetate. Cancer 83:1989-1994, 1998
16. Kelly WK, Scher HI, Mazumdar M, et al: Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer. J Clin Oncol 11:607-615, 1993
17. Scher HI, Kelly WK, Zhang ZF, et al: Post-therapy serum prostate-specific antigen level and survival in patients with androgen-independent prostate cancer. J Natl Cancer Inst 91:244-251, 1999
18. Bauer KS, Figg WD, Hamilton JM, et al: A pharmacokinetically guided phase II study of carboxyamido-triazole (CAI) in androgen independent prostate cancer. Clin Cancer Res (in press)
19. Sartor O, Weinberger M, Moore A, et al: Effect of prednisone on prostate-specific antigen in patients with hormone-refractory cancer. Urol 52:252-256, 1998
20. Petyrlac DP, Macarther RB, O'Connor J, et al: Phase I trial of docetaxal with estramustine in androgen-independent prostate cancer. J Clin Oncol 17:958-967, 1999
21. Dawson NA: Apples and oranges: Building a consensus for standardized eligibility criteria and end points in prostate cancer clinical trials, J Clin Oncol 16:3398-3405, 1998
22. Horti J, Dixon SC, Logothetis C, et al: Increased transcriptional activity of PSA in the presences of TNP-470, an angiogenesis inhibitor. Br J Cancer 79:1588-1593, 1999
23. Wasilenko WJ, Palad AJ, Somers KD, et al: Effect of the calcium influx inhibitor carboxyamido-triazole on the proliferation and invasiveness of human prostate tumor cell lines. Int J Cancer 68:259-264, 1996
24. Pollen JJ, Witztum KF, Ashburn WL: The flare phenomenon on radionucleotide bone scan in metastatic prostate cancer. Am J Roentgenol 142:773-776, 1984
25. Belliveau RE, Spencer RP: Incidence and sites of bone lesions detected by 99mTc-polyphosphate scans in patients with tumor. Cancer 36:259-263, 1975